Selected Publications

Cohesin gene mutations in tumorigenesis

Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldekas K, Kumar A, Simko J, Jensen JB, Bhattacharyya P, Mannion C, Kim JS, Philips G, Dyrskjot L, Waldman T. STAG2 is a biomarker for prediction of recurrence and progression in papillary non-muscle-invasive bladder cancer. Clinical Cancer Research 24: 4145-4153, 2018. [PubMed

Brohl AS, Solomon DA, Chang W, Wang, J, Song YK, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche TJ, Horvai AE, Miettinen M, Wei JS, Catchpoole D, Llombart-Bosch A, Waldman T, Khan J. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genetics 10: e1004475, 2014. [PubMed] [PDF]

Solomon DA, Kim JS, Waldman T. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance. BMB Reports 47: 299-310, 2014. [PubMed] [PDF]

Bailey ML, O’Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma cells containing mutations in the cohesin component, STAG2, are sensitive to PARP inhibition. Molecular Cancer Therapeutics 13: 724-732, 2014. [PubMed] [PDF]

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Kufer R, Hogendoorn PCW, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics 45: 1428-1430, 2013. [PubMed] [PDF]

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky J, Rosenberg SA, Samuels Y, Shukla N, Ladanyi M, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333: 1039-1043, 2011. [PubMed] [PDF]

Brain tumor molecular pathogenesis and targeted therapy

Lopez GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, Samuel D, Siongco A, Raffel C, Gupta N, Kunwar S, Mummaneni P, Aghi M, Theodosopoulos P, Berger M, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica Epub Sept 8, 2018. [PubMed]
Lee J, Putnam AR, Chesier SH, Banerjee A, Raffel C, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Perry A, Solomon DA. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathologica 6: 95, 2018. [PubMed
Phillips JJ, Gong H, Chen K, Joseph NM, Van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Joseph Shieh JT, Solomon DA. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology 29: 85-96, 2019. [PubMed]
Solomon DA, Korshunov A, Sill M, Jones DTW, Kool M, Pfister SM, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Johnston J, Cham E, Cooney T, Sun PP, Oberheim Bush NA, McDermott M, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Villanueva-Meyer JE, Pekmezci M, Bollen AW, Perry A. Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathologica 136: 339-343, 2018. [PubMed]
Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA. The genetic landscape of ganglioglioma. Acta Neuropathologica Communications 6: 47, 2018. [PubMed]
Goode B, Mondal G, Hyun M, Garrido Ruiz D, Lin Y, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications 9: 810, 2018. [PubMed]
Iorgulescu JB, Van Ziffle J, Grenert JP, Bastian BC, Chavez L, Stichel D, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Kool M, Pfister S, Korshunov A, Arie Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals frequent secondary SHH pathway activation.Acta Neuropathologica 135: 635-638, 2018. [PubMed]
Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova N, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, Perry A, Solomon DA. Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathologica 135: 485-488, 2018. [PubMed]
Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology 20: 632-641, 2018. [PubMed]
Lopez GY, Oberheim Bush NA, Phillips JJ, Bouffard JP, Moshel YA, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum MK, Perry A, Solomon DA. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathologica 134: 961-963, 2017. [PubMed]
Wood MD, Tihan T, Perry A, Chacko G, Turner C, Pu C, Payne C, Yu A, Bannykh SI, Solomon DA. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathology 28: 192-202, 2018. [PubMed]
Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AG, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline alterations, and directs targeted therapy. Neuro-Oncology 19: 699-709, 2017. [PubMed]
Cuevas-Ocampo AK, Bollen AW, Goode B, Pajtler KW, Chavez L, Sharma T, Dai SC, McDermott M, Perry A, Korshunov A, Solomon DA. Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathologica 133: 661-663, 2017. [PubMed]
Raleigh D, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic variants and predictive factors for outcome. Neuro-Oncology 19: 78-88, 2017. [PubMed]
Phillips JJ, Gong H, Chen K, Joseph NM, Van Ziffle J, Lin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathologica 132: 757-760, 2016. [PubMed]
Ferris SP, Goode B, Joseph NM, Kline CN, Samuel D, Gupta N, Bollen A, Perry A, Mueller S, Solomon DA. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. Acta Neuropathologica 132: 153-155, 2016. [PubMed]

Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathology Epub Oct 30, 2015. [PubMed] [PDF]

Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris P, Zhang Z, Petritsch C, Gupta N, Waldman T, James CD. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine 20: 1394-1396, 2014. [PubMed] [PDF]

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman T, James CD. Targeted therapy for BRAFV600E malignant astrocytoma. Clinical Cancer Research 17: 7595-7604, 2011. [PubMed] [PDF]

Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Lu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1: 265-277, 2010. [PubMed] [PDF]

Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1 R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications 398: 585-587, 2010. [PubMed] [PDF]

Michaud K*, Solomon DA*, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, and Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Research 70: 3228-3238, 2010. *contributed equally [PubMed] [PDF]

Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. Sample type bias in the analysis of cancer genomes. Cancer Research 69: 5630-5633, 2009. [PubMed] [PDF]

Solomon DA, Kim JS, Yang XR, Tucker MA, Goldstein AM, Samuels Y, Waldman T. Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome. Pigment Cell & Melanoma Research 22: 489-491, 2009. [PubMed] [PDF]

Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Bigner D, Yan H, Rosenberg SA, Ressom H, Jean W, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Research 68: 10300-10306, 2008. [PubMed] [PDF]

Solomon DA, Kim JS, Jean W, Waldman T. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme. Cancer Research 68: 8657-8660, 2008. [PubMed] [PDF]

Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N, Mabanta L, Bigner D, Yan H, Jean W, Waldman T. Identification of p18INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Research 68: 2564-2569, 2008. [PubMed] [PDF]

Mesothelioma molecular pathogenesis

Stevers M, Rabban JT, Garg K, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Zaloudek C, Solomon DA. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Modern Pathology 32: 88-99, 2019. [PubMed]
Goode B, Joseph NM, Stevers M, Van Ziffle J, Onodera C, Talevich E, Grenert JP, Yeh I, Bastian BC, Phillips JJ, Garg K, Rabban JT, Zaloudek C, Solomon DA. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Modern Pathology 31: 660-673, 2018. [PubMed]
Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Modern Pathology 30: 246-254, 2017. [PubMed]


Retinoblastoma, chromatin remodeling, and DNA repair

Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, ,Yaniv M, Muchardt C, Metzger D, Chambon P, Roberts CWM, Knudsen ES. SWI/SNF-deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Molecular Biology of the Cell 20: 3192-3199, 2009. [PubMed] [PDF]

Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, Knudsen ES. RB/p107/p130 pocket proteins: Protein dynamics and interactions with target gene promoters. Journal of Biological Chemistry 284: 19265-19271, 2009. [PubMed] [PDF]

Solomon DA, Cardoso MC, Knudsen ES. Dynamic targeting of the replication machinery to sites of DNA damage. Journal of Cell Biology 166: 455-463, 2004. [PubMed] [PDF]

Angus SP, Mayhew CN, Solomon DA, Braden W, Markey MP, Okuno Y, Cardoso MC, Gilbert DM, Knudsen ES. RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Molecular and Cellular Biology 24: 5404-5420, 2004. [PubMed] [PDF]

Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP, Knudsen ES. Hierarchical requirement of Swi/Snf in RB-mediated repression of Plk1. Journal of Biological Chemistry 279: 29278-29285, 2004. [PubMed] [PDF]

Angus SP*, Solomon DA*, Kuschel L, Hennigan RF, Knudsen ES. Retinoblastoma tumor suppressor: analyses of dynamic behavior in living cells reveal multiple modes of regulation. Molecular and Cellular Biology 23: 8172-8188, 2003. *contributed equally [PubMed] [PDF]

Siddiqui H*, Solomon DA*, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Molecular and Cellular Biology 23: 7719-7731, 2003. *contributed equally [PubMed] [PDF]

Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES. Cyclin D1 splice variants: differential effects on localization, RB phosphorylation, and cellular transformation. Journal of Biological Chemistry 278: 30339-30347, 2003. [PubMed] [PDF]

Regulation of oligodendrocyte myelination

Kim HJ, DiBernardo AB, Sloane JA, Rasband MN, Solomon D, Kosaras B, Kwak SP, Vartanian TK. WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination. Journal of Neuroscience 26: 5849-5859, 2006. [PubMed] [PDF]

Park SK, Solomon D, Vartanian T. Growth factor control of CNS myelination. Developmental Neuroscience 23: 327-37, 2001. [PubMed] [PDF]